Hormone Replacement Therapy Clinical Trial
Official title:
Reference Intervals for 27 Routine Chemistry and Immunoassay Tests in Transgender Adults on Stable Hormone Therapy
This study will find out what the reference intervals are for common blood tests in transgender people taking hormone therapy. Reference intervals help doctors interpret blood test results. They are expressed as two numbers, and most normal results fall between them. If a results fall outside of them, it may be because of a disease. Some blood tests are also affected by normal difference between people, such as age, sex or ethnicity. For these tests, different reference intervals are given for each group of people. Having accurate reference intervals benefits patients because it allows doctors to identify disease faster. Transgender people have a gender identity which does not match their sex characteristics at birth. Gender identity is the feeling of being a gender, and sex is the biological aspects of growing up male or female. Transgender people may use hormone therapy to help change their appearance to fit their gender identity. This involves taking either oestrogen or testosterone. For blood tests which are affected by sex, it is not clear what reference intervals should be used for transgender people who are on hormone therapy. This is because they have a mixture of male and female sex characteristics. Answering this question will allow doctors to identify disease in them faster. The study will take place at cliniQ, at King's College Hospital, which provides health services to transgender people. It will recruit healthy transgender people who attend the clinic for blood tests to monitor their hormone therapy. Participants will fill out a questionnaire, give a urine sample, then have their appointment as normal. Extra tests will also be performed on their blood sample. The aim is to recruit 240 participants. Participant's tests results will then be used to calculate reference intervals. The study is funded by Viapath Group LLP.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04742816 -
Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients
|
Phase 4 | |
| Recruiting |
NCT04453332 -
Effects of Hormone Replacement Therapy on Cardiovascular Risk and Body Composition Parameters
|
N/A | |
| Recruiting |
NCT06353555 -
Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage
|
N/A | |
| Completed |
NCT04758871 -
Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles
|
Phase 4 | |
| Recruiting |
NCT00785317 -
Effects of Estradiol on Menopausal Breast
|
Phase 4 | |
| Not yet recruiting |
NCT04503915 -
Estrogen Supplementation Mode in HRT-FET Cycle: a RCT
|
N/A | |
| Completed |
NCT00463450 -
Efficacy of Gynodian® Depot in Women With Impaired Well-being
|
Phase 3 | |
| Completed |
NCT00319072 -
Hormone Replacement Therapy (HRT) Website Tool
|
Phase 2 | |
| Recruiting |
NCT05166083 -
Investigation of the Perceptual and Acoustic Voice in Trans Man
|
||
| Completed |
NCT05774405 -
Short-term Effects of Transdermal Estradiol on Female COVID-19 Patients
|
Phase 2 | |
| Completed |
NCT01023802 -
The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer
|
N/A | |
| Completed |
NCT01070979 -
Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.
|
Phase 3 | |
| Not yet recruiting |
NCT05122065 -
Menopausal Vaginal Microbiome
|
||
| Withdrawn |
NCT05168865 -
Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients.
|
Phase 4 | |
| Completed |
NCT05072756 -
Opinion of Brazilian Gynecologists on Hormone Therapy for Menopause and Prescriptive Habits
|
||
| Recruiting |
NCT06372119 -
Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)
|
N/A | |
| Not yet recruiting |
NCT06357442 -
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
|
||
| Completed |
NCT00012909 -
Development and Evaluation of a Hormone Replacement Therapy Decision-Aid
|
N/A |